cro.directory
← Back to posts

BIOSECURE Act clinical trial vendor selection pharma

By Carlton Hoyt ·

Modern Catalyst

The BIOSECURE Act entered law on December 18, 2025, as Section 881 of the FY 2026 NDAA, marking a structural pivot in how US pharmaceutical sponsors and contract research organizations (CROs) must evaluate vendor risk. The statute restricts US executive agencies from contracting with biotechnology companies of concern (BCCs), a designation that will ripple across clinical trial networks, site management organizations, and bioanalytical laboratories that depend on federal funding or work within federally regulated supply chains.

The law's enforcement timeline is now the critical variable for procurement teams. OMB must publish the initial list of designated BCCs by December 18, 2026—exactly one year from enactment. However, the real operational impact will unfold over the subsequent 180 days, when OMB and the FAR Council issue implementing guidance for federal agencies. While enforcement could theoretically begin as early as 2026, most legal counsel expect the majority of regulatory machinery to consume the full statutory window, pushing material compliance pressure into mid-to-late 2027.

The BIOSECURE Act's scope extends beyond direct federal contractors. The law is designed to limit Chinese biotechs and manufacturers from accessing US funding and collaborating with US pharma companies using federal funding. This language captures not only NIH-funded trials but also any clinical development pathway that touches federal grant money, Small Business Innovation Research (SBIR) programs, or Defense Department partnerships. For CROs and their subcontractors—particularly those offering bioanalysis, manufacturing support, or regulatory consulting—the definition of "federal funding" will determine exposure.

Structural Impact

Vendor selection for clinical trials in 2026 now requires a three-layer compliance audit that did not exist in 2025.

Layer 1: Direct BCC Designation Risk

Once the December 2026 BCC list is published, any CRO, site management organization, laboratory, or manufacturing partner on that list becomes ineligible for federal contracts and grants. For sponsors running multi-site Phase II or Phase III trials with NIH funding, this creates immediate vendor churn risk. A CRO with Chinese ownership, Chinese board representation, or significant Chinese supply-chain dependencies could face designation. Procurement teams must begin mapping their vendor base now—identifying which CROs have Chinese parent companies, joint ventures, or material sourcing relationships. The first official list of designated companies is expected by December 18, 2026, but the criteria for designation remain opaque until OMB publishes guidance.

Layer 2: Subcontractor and Supply-Chain Exposure

BIOSECURE does not stop at direct vendors. If a CRO subcontracts bioanalysis to a lab with Chinese ownership, or sources reagents from a Chinese biotech, the sponsor's federal funding eligibility may be jeopardized. This cascading liability means procurement teams must now require vendor attestations and supply-chain transparency from every tier. CROs will need to audit their own subcontractors and pass compliance certifications upstream to sponsors. For mid-market CROs without robust vendor management systems, this represents a material operational cost.

Layer 3: Funding-Source Tracking

Not all clinical trials carry equal BIOSECURE risk. A Phase I trial funded entirely by a private equity-backed biotech faces no direct federal compliance burden. A Phase II trial co-funded by an NIH grant or an SBIR award triggers full BIOSECURE scrutiny. Sponsors must now segregate their vendor rosters by funding source and trial phase. This requires new procurement workflows: trials with federal funding get a "BIOSECURE-compliant" vendor list; trials with purely private funding may retain broader vendor optionality. CROs that can offer this flexibility—and document it clearly—will gain competitive advantage.

Capacity and Timeline Implications

The 12-month window before the BCC list publication creates a false sense of runway. In reality, procurement teams should assume that major CROs will begin self-certifying compliance by mid-2026, and that sponsors will demand BIOSECURE attestations in RFPs by Q3 2026. CROs without clear ownership structures, supply-chain maps, and compliance documentation will face delays in contract awards. Smaller, regional CROs with opaque ownership or significant offshore operations may be deprioritized, even if they are not ultimately designated. This consolidation pressure favors large, publicly traded CROs with transparent governance and established compliance infrastructure.

Strategic Blueprint

For Procurement Leaders: Immediate Actions (Q1–Q2 2026)

  1. Audit your vendor base by ownership and geography. Create a spreadsheet of every CRO, site management organization, bioanalytical lab, and manufacturing partner your organization uses. Flag any with Chinese ownership, Chinese board members, or >10% Chinese supply-chain exposure. Do not wait for the BCC list; assume that any material Chinese connection will face scrutiny.
  1. Segregate trials by funding source. Categorize your clinical pipeline by whether each trial receives federal funding (NIH, DOD, SBIR, etc.) or is purely private-funded. For federally funded trials, begin requiring BIOSECURE compliance language in all new vendor contracts by Q2 2026.
  1. Demand vendor attestations. Issue a compliance questionnaire to all active CROs and subcontractors asking for:
  1. Establish a BIOSECURE vendor tier. Create two vendor lists: Tier A (BIOSECURE-compliant, suitable for federally funded trials) and Tier B (unvetted or high-risk, suitable only for private-funded trials). Communicate this clearly to your clinical operations and finance teams.
  1. Negotiate contract amendments now. For existing CRO agreements, add a BIOSECURE compliance clause that requires the vendor to:

For Procurement Leaders: Medium-Term Strategy (Q3 2026–Q1 2027)

Once the BCC list is published in December 2026, expect a 30–60 day scramble. Any vendor on the list will become immediately ineligible for federally funded work. Sponsors will need to:

Procurement teams should pre-position backup vendors for critical functions (bioanalysis, site management, regulatory consulting) by Q3 2026, before the list is published. This reduces post-publication scramble and preserves trial timelines.

For Procurement Leaders: Long-Term Positioning (2027+)

BIOSECURE is the first of likely multiple waves of foreign-ownership restrictions in biotech. Expect similar rules for CDMOs, API manufacturers, and clinical data repositories. Procurement teams should:

Sources

  1. United States: The BIOSECURE Act Becomes Law | Insight | Baker McKenzie
  1. BIOSECURE Act: What You Need to Know | HUB | K&L Gates
  1. BIOSECURE Act Update | Morrison Foerster
  1. BIOSECURE returns to US pharma agenda with 2.0 update - Clinical Trials Arena
  1. BIOSECURE, Tariffs, and the New CDMO Reality for Biopharma Innovators
  1. Final FY 2026 NDAA Includes BIOSECURE Act Provisions and New Opportunities for Biotech as DOD National Security Priority | Insights & Resources | Goodwin
  1. BIOSECURE Act Becomes Law - Akin Gump
  1. BIOSECURE Act included in Senate version of the 2026 NDAA | Hogan Lovells

Markdown mirror: /posts/biosecure-act-clinical-trial-vendor-selection-pharma-cro.md